EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Atypical hemolytic uremic syndrome: pathophysiology, clinical presentation, and treatment strategies

Ji Yeon Song iD

Childhood Kidney Diseases · 27.06.2025 · 29 (2) · 52-59

DOI: 10.3339/ckd.25.017 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Childhood Kidney Diseases, online erschienen am 27.06.2025. Verfasst von Ji Yeon Song. Beteiligte Einrichtung: Department of Pediatrics, Pusan National University Children's Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Pusan National University Yangsan Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atypical hemolytic uremic syndrome (aHUS) is a rare and potentially life-threatening thrombotic microangiopathy, characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Without timely intervention, it may progress to end-stage kidney disease. The condition is primarily attributed to dysregulation of the alternative complement pathway, with up to 60% of patients exhibiting genetic mutations in complement regulatory proteins such as complement factor H, complement factor I, membrane cofactor protein, and thrombomodulin. The introduction of complement inhibitors, such as eculizumab and ravulizumab, has significantly improved clinical outcomes by reducing recurrence and preserving renal function. These advances have redefined treatment approaches, particularly in pediatric patients and those undergoing kidney transplantation. The prophylactic use of complement inhibitors is now recommended for transplant recipients with moderate to high genetic risk. This review aimed to examine the pathophysiology, clinical manifestations, and treatment strategies of aHUS. Early and targeted complement inhibition is essential for preventing irreversible kidney damage and optimizing outcomes, particularly in children and transplant recipients.

Schlagwörter

Stichwörter der Autor:innen

Alternative complement pathwayAtypical hemolytic uremic syndromeComplement inactivating agentsKidney transplantationPediatrics

Autor:innen und Institutionen

  • Department of Pediatrics, Pusan National University Children's Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea.

ORCID-Profile: Ji Yeon Song

Förderung

  • Pusan National University Yangsan Hospital

Zitieren

APA

Song, J. Y. (2025). Atypical hemolytic uremic syndrome: pathophysiology, clinical presentation, and treatment strategies. Childhood Kidney Diseases, 29(2), 52-59. https://doi.org/10.3339/ckd.25.017

Vancouver

Song JY. Atypical hemolytic uremic syndrome: pathophysiology, clinical presentation, and treatment strategies. Childhood Kidney Diseases. 2025;29(2):52-59. doi:10.3339/ckd.25.017

BibTeX
@article{Song2025,
  author = {Song, Ji Yeon},
  title = {Atypical hemolytic uremic syndrome: pathophysiology, clinical presentation, and treatment strategies},
  journal = {Childhood Kidney Diseases},
  year = {2025},
  volume = {29},
  number = {2},
  pages = {52--59},
  doi = {10.3339/ckd.25.017}
}
Kostenlos starten →